The MHC encodes antigen presenting molecules that display peptide fragments to T cells to initiate immune responses. It contains three regions - Class I MHC presents intracellular peptides to CD8+ T cells, Class II MHC presents extracellular peptides to CD4+ T cells, and Class III MHC encodes complement proteins. MHC molecules are highly polymorphic and individuals inherit multiple alleles from each parent. This polymorphism allows presentation of a wide range of peptides and enhances immune responses against pathogens. MHC matching is important for transplantation, as mismatch can lead to graft rejection through T cell recognition of foreign MHC.
IT CONTAINS THE LATEST INFORMATION ABOUT MHC MOLECULE WHICH WILL BE HELPFUL FOR B.SC /M.SC/CSIR-NET/DBT-JRF/GATE STUDENTS. THIS IS IN VERY SIMPLE AND LUCID MANNER TO UNDERSTAND AND ONE CAN EASILY OPT FOR THIS TO PREPARE NOTES.
IT CONTAINS THE LATEST INFORMATION ABOUT MHC MOLECULE WHICH WILL BE HELPFUL FOR B.SC /M.SC/CSIR-NET/DBT-JRF/GATE STUDENTS. THIS IS IN VERY SIMPLE AND LUCID MANNER TO UNDERSTAND AND ONE CAN EASILY OPT FOR THIS TO PREPARE NOTES.
An undergraduate lecture on immunologic tolerance, it's various types and how a breakdown of tolerance contributes to the pathogenesis of autoimmune diseases. Additionally a small quiz at the end to gauge the students' learning.
It is in these organs where the cells of the immune system do their actual job of fighting off germs and foreign substances.
Bone marrow. Bone marrow is a sponge-like tissue found inside the bones. ...
Thymus. The thymus is located behind the breastbone above the heart. ...
Lymph nodes. ...
Spleen. ...
Tonsils. ...
Mucous membranes.
An undergraduate lecture on immunologic tolerance, it's various types and how a breakdown of tolerance contributes to the pathogenesis of autoimmune diseases. Additionally a small quiz at the end to gauge the students' learning.
It is in these organs where the cells of the immune system do their actual job of fighting off germs and foreign substances.
Bone marrow. Bone marrow is a sponge-like tissue found inside the bones. ...
Thymus. The thymus is located behind the breastbone above the heart. ...
Lymph nodes. ...
Spleen. ...
Tonsils. ...
Mucous membranes.
History
Introduction
Classification of grafts
The Immunology of Allogeneic Transplantation
Genetics of graft rejection
Types of rejection
Recognition of Alloantigens
Effector Mechanisms of Allograft Rejection
Prevention of graft rejection
Graft versus host reaction
major histocompatibility cells and its role in immunity. one of the main mechanisms of innate and acquired immunity in human body defense mechanism. it includes both the major and minor forms and different types of cells that are involved in. difference between innate and acquired immunity and its role in autoimmune disorders. the concept of advanced immunology. modern concepts in immunology.
minor histocompatibility molecules. definition and functions of major histocompatibilty molecules. role in autoimmune disorders. immunology and micro-invironment. role of genetics in immunity. minor cells are lymphocytes and plasma cells. acute cells are neutrophils or PMNLS. ROLE OF INFLAMMATIO IN IMMUNITY. role of cell membrane receptors in immunity and immune-mediated diseases.
2. HLA human leukocyte antigens:
Alloantigen – differ among members of same species
present on surface of cells, encoded on HLA genes
Genes clustered on MHC, located on short arm of chromosome6.
HLA Genes
HLA-A, HLA-B, HLA-C → Class I MHC proteins
HLA-D → DP, DQ, DR → Class II MHC proteins
Class III Genes for → C2, C4, TNF, Lymphotoxin LT
2 haplotypes, maternal and paternal sets
Polymorphic (many alleles) HLA-A – 47, HLA-B – 88, HLA-C – 29, HLA-D - 300
3. Every person has single allele at each locus. So inherit
two haplotypes – 1 maternal on chromosome 6, 1 paternal set.
Each allele can make 2 class I & 2 class II proteins. Co- dominant. Proteins by both are expressed.
Each person can make 12 HLA proteins 3 each at class I and II loci, from both chromosomes
Minor antigens by genes at other sites. Body proteins with 1 or more different amino acid → weak immune response → slow rejection of graft.
4. Class I MHC: glycoprotein. Present on All nucleated cells
20 proteins encoded by A, 40 by B, 8 by C gene locus
45,000 Mol. wt. Heavy chain non covalently bound to β2 microglobulin. Similar to Ig molecule. Highly polymorphic. Importance is recognition of self & non self. Hypervariable region at N terminal region. constant region binds to CD 8 of cytotoxic T cell
5. Class II MHC: glycoprotein. Highly polymorphic
Present on Macrophages, B cell, Dendritic cell Spleen, Langerhans cell (skin)
Made up of 2 polypeptides (mol wt. 33000, 28000) non covalently bound. Constant region for CD4 protein of helper T cell
Functions of Major Histocompatibility Complex MHC
1. Positive selection of T cells in thymus
2. Antigen presentation
6. Present antigens to T cells which recognize antigen only if associated to self class I or II MHC → immune response - MHC restriction.
Success of organ or tissue transplant - compatibility of donor & recipient MHC genes. If HLA proteins differ → immune response → rejection of graft. Minor antigens → slow rejection.
Autoimmune diseases: occur in individuals who carry
certain MHC genes
7. Auto graft: Transfer of individuals own tissue to another site in the body. Permanently accepted
Syngeneic graft: Transfer of tissues between genetically identical individuals e.g identical twins
Xenograft: Transfer between different species.
Allograft: Transfer between members of same species. Usually rejected unless immunosuppressive drugs given e.g from one human to another.
8. Allografts are rejected by a process known as allograft reaction.
In an acute allograft reaction;
vascularization of the graft is normal initially, but in 11-14 days, marked reduction in circulation and mononuclear cell infiltration occurs, with eventual necrosis.
This is called a primary (first-set) reaction
A T-cell-mediated reaction is the main cause of rejection of many types of grafts, e.g., skin, but antibodies contribute to the rejection of certain transplants, especially bone marrow
9. If a second allograft from the same donor is applied to a sensi
Dr. ihsan edan abdulkareem alsaimary
PROFESSOR IN MEDICAL MICROBIOLOGY AND MOLECULAR IMMUNOLOGY
ihsanalsaimary@gmail.com
mobile : 009647801410838
university of basrah - college of medicine - basrah -IRAQ
introduction, history, classification of grafts, transplantation antigens, role of MHC in transplantation, immunology of allogenic transplantation, types of graft rejection, immunology of xenogeneic transplatation, organ trannsplantation.
In class presentation for an advanced cell biology course at KSU, fall 2017. Background knowledge includes a previous immunology course, about 6 biochemistry courses and research.
JMeter webinar - integration with InfluxDB and GrafanaRTTS
Watch this recorded webinar about real-time monitoring of application performance. See how to integrate Apache JMeter, the open-source leader in performance testing, with InfluxDB, the open-source time-series database, and Grafana, the open-source analytics and visualization application.
In this webinar, we will review the benefits of leveraging InfluxDB and Grafana when executing load tests and demonstrate how these tools are used to visualize performance metrics.
Length: 30 minutes
Session Overview
-------------------------------------------
During this webinar, we will cover the following topics while demonstrating the integrations of JMeter, InfluxDB and Grafana:
- What out-of-the-box solutions are available for real-time monitoring JMeter tests?
- What are the benefits of integrating InfluxDB and Grafana into the load testing stack?
- Which features are provided by Grafana?
- Demonstration of InfluxDB and Grafana using a practice web application
To view the webinar recording, go to:
https://www.rttsweb.com/jmeter-integration-webinar
The Art of the Pitch: WordPress Relationships and SalesLaura Byrne
Clients don’t know what they don’t know. What web solutions are right for them? How does WordPress come into the picture? How do you make sure you understand scope and timeline? What do you do if sometime changes?
All these questions and more will be explored as we talk about matching clients’ needs with what your agency offers without pulling teeth or pulling your hair out. Practical tips, and strategies for successful relationship building that leads to closing the deal.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Elevating Tactical DDD Patterns Through Object CalisthenicsDorra BARTAGUIZ
After immersing yourself in the blue book and its red counterpart, attending DDD-focused conferences, and applying tactical patterns, you're left with a crucial question: How do I ensure my design is effective? Tactical patterns within Domain-Driven Design (DDD) serve as guiding principles for creating clear and manageable domain models. However, achieving success with these patterns requires additional guidance. Interestingly, we've observed that a set of constraints initially designed for training purposes remarkably aligns with effective pattern implementation, offering a more ‘mechanical’ approach. Let's explore together how Object Calisthenics can elevate the design of your tactical DDD patterns, offering concrete help for those venturing into DDD for the first time!
Neuro-symbolic is not enough, we need neuro-*semantic*Frank van Harmelen
Neuro-symbolic (NeSy) AI is on the rise. However, simply machine learning on just any symbolic structure is not sufficient to really harvest the gains of NeSy. These will only be gained when the symbolic structures have an actual semantics. I give an operational definition of semantics as “predictable inference”.
All of this illustrated with link prediction over knowledge graphs, but the argument is general.
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Generating a custom Ruby SDK for your web service or Rails API using Smithyg2nightmarescribd
Have you ever wanted a Ruby client API to communicate with your web service? Smithy is a protocol-agnostic language for defining services and SDKs. Smithy Ruby is an implementation of Smithy that generates a Ruby SDK using a Smithy model. In this talk, we will explore Smithy and Smithy Ruby to learn how to generate custom feature-rich SDKs that can communicate with any web service, such as a Rails JSON API.
Software Delivery At the Speed of AI: Inflectra Invests In AI-Powered QualityInflectra
In this insightful webinar, Inflectra explores how artificial intelligence (AI) is transforming software development and testing. Discover how AI-powered tools are revolutionizing every stage of the software development lifecycle (SDLC), from design and prototyping to testing, deployment, and monitoring.
Learn about:
• The Future of Testing: How AI is shifting testing towards verification, analysis, and higher-level skills, while reducing repetitive tasks.
• Test Automation: How AI-powered test case generation, optimization, and self-healing tests are making testing more efficient and effective.
• Visual Testing: Explore the emerging capabilities of AI in visual testing and how it's set to revolutionize UI verification.
• Inflectra's AI Solutions: See demonstrations of Inflectra's cutting-edge AI tools like the ChatGPT plugin and Azure Open AI platform, designed to streamline your testing process.
Whether you're a developer, tester, or QA professional, this webinar will give you valuable insights into how AI is shaping the future of software delivery.
Essentials of Automations: Optimizing FME Workflows with ParametersSafe Software
Are you looking to streamline your workflows and boost your projects’ efficiency? Do you find yourself searching for ways to add flexibility and control over your FME workflows? If so, you’re in the right place.
Join us for an insightful dive into the world of FME parameters, a critical element in optimizing workflow efficiency. This webinar marks the beginning of our three-part “Essentials of Automation” series. This first webinar is designed to equip you with the knowledge and skills to utilize parameters effectively: enhancing the flexibility, maintainability, and user control of your FME projects.
Here’s what you’ll gain:
- Essentials of FME Parameters: Understand the pivotal role of parameters, including Reader/Writer, Transformer, User, and FME Flow categories. Discover how they are the key to unlocking automation and optimization within your workflows.
- Practical Applications in FME Form: Delve into key user parameter types including choice, connections, and file URLs. Allow users to control how a workflow runs, making your workflows more reusable. Learn to import values and deliver the best user experience for your workflows while enhancing accuracy.
- Optimization Strategies in FME Flow: Explore the creation and strategic deployment of parameters in FME Flow, including the use of deployment and geometry parameters, to maximize workflow efficiency.
- Pro Tips for Success: Gain insights on parameterizing connections and leveraging new features like Conditional Visibility for clarity and simplicity.
We’ll wrap up with a glimpse into future webinars, followed by a Q&A session to address your specific questions surrounding this topic.
Don’t miss this opportunity to elevate your FME expertise and drive your projects to new heights of efficiency.
2. THE MHC
• Is the gene region located on chromosomes 6 in
humans and it encodes the antigen presenting
cells molecules designated class I MHC and class II
MHC.
• In between the two region MHC I and MHC II are
the class III MHC genes that encodes some of the
complement proteins.
• Both classes of MHC molecules consists of two
polypeptide chains non covalently associated.
3. MHC
• each class of MHC has three distinct forms:-
Class I MHC- HLA-A, HLA-B and HLA-C
Class II MHC – HLA-DP, HLA-DQ, HLA-DR
Class II MHC genes Class I MHC genes
HLA-DP,HLA-DQ,HLA-DR HLA-B,HLA-C,HLA-A
00 00 00 0 0 0
4. MHC
• The total set of MHC alleles class I and II inherited
from one parent is haplotypes (seen genotype)
• Each form MHC has several alleles(variants) in the
population.
• Each allelic variants can potentially bind a
number of antigen peptides.
• When a peptide binds to MHC molecules, the
complex formed subsequently displayed in the
cell surface, where it can be recognized by T cell
5. MHC
• In effect ,these complex alert T cell that a foreign
substance (micro-organism) is present.
• Recognization of these complexes is required for
T cells activation, which is a requirement for most
adaptive immune responses.
• The genes that determined the out come of the
graft were referred as the histocompatibility
genes and the proteins encoded to the genes
histocompatibility antigen.
6. CLASS I MHC IN HUMAN
• Three forms of class I MHC proteins can be
identified in all human nuclear cells.
• There molecule form a complex with antigen
fragments within the cells and the complex is
displayed on a cell surface.
7. DISCOVERY OF CLASS I MHC
• Mouse was used in experiments (skin grafts)
• Human blood transfusion was used ( graft)
because cells are transfused from one
individual to another.
• Therefore ,individual who had received a
foreign graft (blood transfusion) or mother
who had several pregnancies (multiparous)
were identified as graft recipients ( serum
tested for anti-MHC antibodies).
8. • Individual who have received blood transfusions
would have generated antibodies specific for the
MHC antigens present on transfused blood cells.
• For mothers who had several pregnancies is that
lymphocytes from the fetus enter the maternal
circulation during delivery.
• Since fetal lymphocytes expresses paternal MHC
antigens (as well as the mother MHC antigens)the
fetal cells are foreign grafts.
9. • the mother’s immune system would be activated
in response to the foreign MHC and would lead to
the production of anti-MHC (paternal antibodies).
• Because MHC molecules to which antibodies
were generated were present in the human
leukocytes these MHC molecules were called
human leukocytes antigen and the gene locus
that encoded them the HLA locus.
• The HLA locus is synonym with MHC locus the
genetic term for this region.
10. Description of class I MHC
Two polypeptides
• Polymorphic heavy chain MHC locus
chromosome 6.
• Non polymorphic light chain (B2
microglobulin)- chromosome 15
11. Class I MHC polymorphism and
Nomenclature
• Each HLA (A,B,C) gene has many allelic variant
forms in the population (polymorphic)
• HLA-A1 HLA-A2 HLA-A3 and so on.
12. Expression of class I MHC
• Each of three forms of class I MHC are
co-dominantly expressed.
• The three class I alleles (variants)inherited from
each parents are expressed on the cell.
examples
the child inherits the following alleles from one
parent (HLA-A ,HLA-B8 and HLA-Cw4) and the
following alleles from the parent( HLA- A2,HLA-
B37 and HLA-Cw7) all six different molecules will
be present on the child nucleated cells.
15. CLASS II MHC
• Three forms of class II MHC can be identified
on antigen presenting cells.
• These molecules bind antigen fragments
within a cystolic vacuole and the complex is
then displayed on the surface of the antigen
presenting.
16. Discovery of class II MHC
• The human class II MHC gene region known as
the HLA-D region was identified using the mixed
leukocyte reaction (MLR)
• MLR is a laboratory technique used as a
predictive test for graft rejection.
• This assay is used to determine whether T cells
forms one individual will be activated when they
interact with class II MHC protein present on
another individual cells(allogenic MHC).
17. • HLA-D region consisted of three gene loci
HLA-DP ,HLA-DQ, HLA-DR
Examples
In individual who are genetically identical
(monozygotic twins)T cells will not be activated in
MLR on the other hand. If two individuals are
genetically desperate the CD4+ T cells recognizing
the class MHC proteins as foreign and respond by
proliferation.
18. Description of class II MHC
• They are comprised of two poly peptide chains
( alpha and beta).each chain is polymorphic and
the genes that encodes them are located within
the MHC locus
• For the most part, class II MHC molecules are
normally Expressed on antigen presenting cells (B
cells, monocytes, macrophases and dendrite
cells)
• Exposure to some cytokins can enhance the
number of class II MHC molecules expressed on
an antigen presenting cells.
19. Class II MHC polymorphism and
Nomenclature
• Each HLA-D (DP,DQ,DR) gene has many allelic
variants or forms in a population and so the
HLA-D genes are said to be polymorphic.
• Each gene variant (allele) is given a number
example
HLA-DR alleles are numbered
HLA-DR1 , HLA-DR2
20. Expression of class II MHC
• Class II molecules are co-dominantly expressed.
• Each class is different various combination of
polypeptide are possible
• When a child inherits two entirely different sets
of alleles at least 12 different combination.
(four for each HLA-DR,DP,DQ) are possible,
however not all combinations will be represented
equally because some combinations are more
stable than others.
21. Examples
if a child inherits HLA-DR1 which is comprised
of sigma(1) and beta(1) from the one parent
and HLA-DR4 comprised of alpha(4) and
beta(4) from the other parent, the number of
possible combinations of HLA-DR on the cell
surface would be (HLA-DR (1)/ (1) ,HLA-DR
(4)/ (4) ,HLA-DR (1)/ (4) and HLA-DR (4)/ (1)
22. • The expression of so many different class II
MHC molecules on an antigen presenting cells
greatly increase the liklihood that an antigen
peptide will form a complex with an MHC
protein and be presented on the cell surface
of the T cells to recognize.
25. Role of MHC in immune response
• Based on the studies the MHC gene loci were
aimed to identify those molecule that were
involved in graft rejection.
• Important molecules in host defense
• In normal host immune response, antigenic
peptides are displayed on cell surfaces
complexed with MHC molecules.
26. • Cytotoxic T cells (CD8+ T cell) recognize
antigen peptide complexed with a class I MHC
molecules on the cell surface.
• In contrast helper T cells ( CD4+ T cell) will
recognize antigen peptide displayed with a
class II MHC molecules
27. Importance
• A sucessful immune response, demands that
helper T cells (CD4+) are activated, and this
can only occur if antigenic displayed on the
cells surface in association with class II MHC
• In turn, experiment of that complex requires
that one of the inherited MHC alleles is
capable of binding one of antigen peptides
generated in the phagocytosis vacoule.
28. Transplantation immunology
Transplantation
• Is there process where by an individual
(recepient) receives cells or tissues from a 2nd
individual (donar)
29. classification
• Isograft :-graft in which there is no genetic
different between donar and receipent
(genetically identical individual)
• Allograft:- graft between the member of same
species
• Xenograft:-graft across a species
• Autograft:-self tissue transferred from one
body site to another in the same individual.
30. • For some part ,transplants are allografts are so
there is a genetic disparity betwn the donar
and receipent (MHC loci)
• To some extent the MHC genetic disparity
determine whether a graft will be accepted or
rejected becoz the proteins( antigens) that
they encode have been shower to induce the
most vigrous rejection episodes.
31. Graft rejection
• Immunologic response of a transplant
receipent to the cells of the graft from a non-
histocompatible donor.
32. classification
1.Hyperacute rejection
• Occurs minutes to 1 hour following the
engraftment.
• Antibody mediated phenomenon and is
associated with complement activator, blood
clot formation and rapid graft failure.
• Indicates that the recipient has been
previously exposed to the donor MHC antigen
• Graft removal
33. Acute rejection
• Occurs week after tissue transplant and is
caused by helper and cytotoxic T-cell
activation (cell mediated)
34. Chronic Rejection
• May occur weeks, months or years Post
transplant.
• Associated with a notable increase in the
levels of non T cell derived non specific
growth factors.
• No treatment, graft must be removed
• Humoral and cell mediated.
35. Rejection in bone marrow
transplantation
• Used to treat leukemias and lymphocytes
• These types of transplants are unique in that
the donor cells attack the receipent tissues.
• Referred to as graft versus host disease(GVHD)
• T cells present in the graft are stimulated
becoz the recipient is recognized as foreign.
• Recipients are seriously immunocompromised
and so their immune system cannot attack the
graft with the same intensity.
36. Immunosupressive therapies
• Because acute rejection a T- cell mediated event,
many of the therapies target the T-cells
• Treatment for acute rejection consists of
increasing dose of immunosuppressive drugs.
• Commonly used drugs are cyclopshorin A and
FK506 which block the production of a T cell
growth factor
• Prednisone is used as non specific anti-
inflammatory agent, targets macrophages and
reduced antigen presentation of T cells.
37. Screening to ensure compatibility
• Recipients and potential donor, are pre-
screened to ensure the best possible genetic
match at MHC loci to minimize rejection.
• The pre-transplantation screening test are
based on serological cellular and molecular
typing techniques
• Pre-transplantation testing is more commonly
referred as histocompatibility testing and
includes tissue matching and tissue typing.
39. serologic approach
• Donor and recipient tissues are reacted
separately with panels of antibodies for
various MHC alleles and their relation are
compared.
• The problem with this approach is that allelic
difference can be detected only if an antibody
is available for the allele.
40. Cellular approach
• Used mixed leukocyte reaction (MLR)
• Donor and recipient cells are cultured together
for several classes to allow T cells to be activated
and proliferate in response to disparate MHC
proteins.
• The amount of proliferation can be measured and
used to predict the magnitude of rejection.
• Bone marrow transplant and cases of related
donor.
41. Molecular approach
• Used restriction fragment length
polymorphism(RFLP) and the polymerase
chain reaction (PCR)
• RFLP- enzymes are used to cleave genomic
DNA to obtain a pattern of fragmentation
• The genetic disparity between the donor and
recipient can be assessed by comparing
pattern of fragmentation.
42. PCR
• Directs amplification of a particular DNA
sequence selected by use of primers (short
nucleic acid sequence)that border the genes
of interest.
• The degree of disparity betwn the recipients
and the donor for the selected sequences can
be determined.
43. Tissue testing
• Individuals HLA genotype
• PCR is the method of choice.
• Serologic approach- incubation of the
individuals blood with panel of antibody of
known specificity
44. Paternity and histocompatibility
testing
• Histocompatibility testing may also be used to
determine paternity.
• In this situation, paternity is not confirmed.
• The test is based on exclusion.
• If the child does not express any/ the same
HLA alleles as the male being tested, paternity
can be excluded.
45. • Organs – tissue that can be transplanted from
human
• Kidney liver
heart skin
lungs cornea
pancreas blood
bone marrow cord blood